Literature DB >> 11190005

Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C.

L Kleinman1, M W Zodet, Z Hakim, J Aledort, C Barker, K Chan, L Krupp, D Revicki.   

Abstract

Evidence exists demonstrating that infection with hepatitis C virus impairs health-related quality of life, but less is known about the effect of fatigue, a common symptom, on everyday life. The psychometric properties of the fatigue severity scale (FSS) were explored to determine suitability as an outcome measure in clinical trials. The FSS includes nine items developed to measure disabling fatigue and a visual analog scale (VAS) to measure overall fatigue. Using baseline data from three clinical trials (n = 1225) involving chronic hepatitis C patients, scaling and psychometric characteristics of the FSS were assessed. The SF-36 was also used in the trials. Item response theory analysis demonstrated that the FSS items can be placed along a single homogenous domain, fatigue. Internal consistency reliability was 0.94. Test-retest reliability was 0.82 for the total score and 0.80 for the VAS. The total score and the VAS were significantly correlated with the SF-36 vitality subscale (r = -0.76 and r = -0.76 respectively). Correlations with other SF-36 subscales were moderate (r = -0.46 to r = -0.67, all p < 0.0001). In summary, the FSS possesses good psychometric properties.

Entities:  

Mesh:

Year:  2000        PMID: 11190005     DOI: 10.1023/a:1008960710415

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  13 in total

Review 1.  Generic and disease-specific measures in assessing health status and quality of life.

Authors:  D L Patrick; R A Deyo
Journal:  Med Care       Date:  1989-03       Impact factor: 2.983

2.  Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

Authors:  H L Bonkovsky; J M Woolley
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

Review 3.  Side effects of alpha interferon in chronic hepatitis C.

Authors:  G Dusheiko
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

4.  Health assessment for chronic HCV infection: results of quality of life.

Authors:  R L Carithers; D Sugano; M Bayliss
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group.

Authors:  J E Ware; M S Bayliss; M Mannocchia; G L Davis
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

6.  Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients.

Authors:  A Barkhuizen; H R Rosen; S Wolf; K Flora; K Benner; R M Bennett
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

7.  Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients.

Authors:  M P Neary; S Cort; M S Bayliss; J E Ware
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

9.  Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis.

Authors:  G R Foster; R D Goldin; H C Thomas
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

10.  Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  Clin Ther       Date:  1994 Mar-Apr       Impact factor: 3.393

View more
  53 in total

Review 1.  Fatigue in multiple sclerosis: definition, pathophysiology and treatment.

Authors:  Lauren B Krupp
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Fatigue in primary biliary cirrhosis.

Authors:  Ghulam Abbas; Roberta A Jorgensen; Keith D Lindor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-05-11       Impact factor: 46.802

3.  Can EQ-5D and 15D be used interchangeably in economic evaluations? Assessing quality of life in post-stroke patients.

Authors:  Lene Lunde
Journal:  Eur J Health Econ       Date:  2012-06-08

4.  Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals.

Authors:  Giovanni Schifitto; Lijuan Deng; Tzu-Min Yeh; Scott R Evans; Thomas Ernst; Jianhui Zhong; David Clifford
Journal:  J Neurovirol       Date:  2010-12-23       Impact factor: 2.643

5.  Evidence for classically conditioned fatigue responses in patients receiving chemotherapy treatment for breast cancer.

Authors:  Dana H Bovbjerg; Guy H Montgomery; George Raptis
Journal:  J Behav Med       Date:  2005-06

6.  The Flinders Fatigue Scale: preliminary psychometric properties and clinical sensitivity of a new scale for measuring daytime fatigue associated with insomnia.

Authors:  Michael Gradisar; Leon Lack; Hayley Richards; Jodie Harris; Julie Gallasch; Michelle Boundy; Anna Johnston
Journal:  J Clin Sleep Med       Date:  2007-12-15       Impact factor: 4.062

7.  A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24-28, 2013 • Amsterdam, The NetherlandsSpecial Reporting on:• Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection• Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients• Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2/3 Populations• Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir• Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I. Weill Medical College at Cornell UniversityNew York, New York.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-06

8.  Identifying clinically meaningful fatigue with the Fatigue Symptom Inventory.

Authors:  Kristine A Donovan; Paul B Jacobsen; Brent J Small; Pamela N Munster; Michael A Andrykowski
Journal:  J Pain Symptom Manage       Date:  2008-05-20       Impact factor: 3.612

9.  Fatigue in patients with spinal muscular atrophy type II and congenital myopathies: evaluation of the fatigue severity scale.

Authors:  Ulla Werlauff; A Højberg; R Firla-Holme; B F Steffensen; J Vissing
Journal:  Qual Life Res       Date:  2013-11-09       Impact factor: 4.147

10.  Fatigue: an important feature of late-onset Pompe disease.

Authors:  Marloes L C Hagemans; Sabine P M van Schie; A Cecile J W Janssens; Pieter A van Doorn; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.